Dachaigh › Cancer briste triple-negative › Pennsylvania › Philadelphia
Sgrùdaidhean clionaigeach Cancer briste triple-negative ann an Philadelphia, PA
Tha 13 sgrùdaidhean airson Cancer briste triple-negative a’ lorg phàirtichean aig làraichean ann agus timcheall air Philadelphia (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Study of AVZO-021 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Avenzo Therapeutics Recruiting Site, Philadelphia
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
A’ fastadhÌre 3
- Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
A’ fastadhÌre 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A’ fastadhÌre 3
- University of Pennsylvania Abramson Cancer Center, Philadelphia
- Lankenau Medical Center, Wynnewood · 7 mìle air falbh
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
A’ fastadhÌre 1
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
A’ fastadhÌre 2/3
- Abramson Cancer Center of The University of Pennsylvania, Philadelphia
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
A’ fastadhÌre 2
- University of Pennsylvania (U Penn), Philadelphia
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
A’ fastadhÌre 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
A’ fastadhÌre 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
A’ fastadh
- Thomas Jefferson University Hospital, Philadelphia
Role of the Immune Environment in Response to Therapy in Breast Cancer
A’ fastadhSgrùdadh amharc
- Abramson Cancer Center, Philadelphia
Sgrùdaidhean Cancer briste triple-negative ann am bailtean eile
- Houston, TX42 sgrùdaidhean
- New York City, NY31 sgrùdaidhean
- Nashville, TN28 sgrùdaidhean
- Los Angeles, CA27 sgrùdaidhean
- Boston, MA26 sgrùdaidhean
- San Antonio, TX23 sgrùdaidhean
- St. Louis, MO21 sgrùdaidhean
- Arlington, VA20 sgrùdaidhean
- Atlanta, GA20 sgrùdaidhean
- Dallas, TX18 sgrùdaidhean
- Chicago, IL16 sgrùdaidhean
- Columbus, OH16 sgrùdaidhean
Sgrùdaidhean eile ann an Philadelphia
- Aillse (gach seòrsa)59 sgrùdaidhean
- Aillse a' bhroilleach56 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag51 sgrùdaidhean
- Ailse metastatach46 sgrùdaidhean
- Aillse Prostata44 sgrùdaidhean
- Aillse colorectal44 sgrùdaidhean
- Cancer Ovarian44 sgrùdaidhean
- Ailseachadh nan Sgamhan36 sgrùdaidhean
- Leukemia myeloid geur34 sgrùdaidhean
- Fàilligeadh a' Chridhe31 sgrùdaidhean
- Ailse Endometrial28 sgrùdaidhean
- Depression26 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.